top of page

CHMP adopts positive opinion of haemophilia B treatment, Alprolix

Swedish Orphan Biovitrum (Sobi) and Biogen have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending that marketing authorisation be granted for Alprolix (rFIXFc) for the treatment of haemophilia B.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page